Updated Jul 16, 2026
Leheny A. Rachel has filed 1 SEC Form 4 filing across 1 company in the last 90 days — buying. Lifetime open-market purchases: $85K. Historical track record: 1/5 stars across 3 tracked purchases.
A. Rachel Leheny is the Chief Executive Officer of CalciMedica, Inc., a clinical-stage biopharmaceutical company focused on developing therapeutics for serious inflammatory and immunologic conditions. She has been involved in the company's operations and strategic direction, although specific public achievements are not widely documented.
| Role | Insider |
|---|---|
| Notability | 30/100 |
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.
| InsiderAlpha rating | ★☆☆☆☆ (1/5) |
|---|---|
| Total purchases tracked | 3 |
| Purchases with forward-return data | 3 |
| 30-day win rate | 3333% |
| 90-day win rate | 3333% |
| Avg 5-day return | +1881.66% |
| Avg 30-day return | -718.10% |
| Avg 90-day return | +142.86% |
| Best 30-day return | +193.97% |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-29 | CALC | CalciMedica, Inc. | A — Grant or award | 186.7K | $0.80 | $150K |
| 2025-07-21 | CALC | CalciMedica, Inc. | P — Open-market purchase | 1.0K | $3.40 | $3K |
| 2025-07-14 | CALC | CalciMedica, Inc. | P — Open-market purchase | 2.5K | $2.47 | $6K |
| 2024-11-01 | CALC | CalciMedica, Inc. | P — Open-market purchase | 20.0K | $3.75 | $75K |
A. Rachel Leheny is the Chief Executive Officer of CalciMedica, Inc., a clinical-stage biopharmaceutical company focused on developing therapeutics for serious inflammatory and immunologic conditions. She has been involved in the company's operations and strategic direction, although specific public achievements are not widely documented.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 3 open-market purchases ($85K) and 0 open-market sales () across all tracked filings.
Across 3 tracked purchases, Leheny A. Rachel averaged -718.1% avg 30-day return with a 3333% 30-day win rate. InsiderAlpha rates the track record at 1/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Leheny A. Rachel profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.